Open an account

Werewolf Therapeutics

HOWL · NASDAQ

$1.05+$0.01 (+0.96%)TodayMarket closed ·
Prev close $1.04

About HOWL

Werewolf Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company is headquartered in Watertown, Massachusetts and currently employs 39 full-time employees. The company went IPO on 2021-04-30. The company is leveraging its PREDATOR platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Its INDUKINE molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. The Company’s advanced clinical-stage product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and IL-12 INDUKINE molecules for the treatment of solid tumors. The company is advancing WTX-124 in multiple tumor types as a single agent and in combination with an immune checkpoint inhibitor. The company is advancing WTX-712, WTX-518, and WTX-921 through preclinical development.

Employees
39
Headquarters
Watertown, Massachusetts
Listed
Apr 30, 2021
Sector
Health Care
Industry
Biotechnology
Website
werewolftx.com

HOWL key statistics

Market cap
51.03M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
479.99K
Volume
485.74K
Open price
$1.03
High today
$1.09
Low today
$1.03
52 Week high
$1.83
52 Week low
$0.27

Werewolf Therapeutics (HOWL) at a glance

As of Oct 20, 2026, Werewolf Therapeutics (HOWL) shares are priced at $1.05, giving the company a market cap of 51.03M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.03 and $1.09. The current price is 1.9% above the day's low and 3.7% below its high.

Volume so far is 485.74K shares, in line with the average of 479.99K shares a day.

Over the past year Werewolf Therapeutics has ranged from $0.27 to $1.83, and now sits 50% of the way up that range.

Werewolf Therapeutics met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q2 FY26 it reported $0.08 per share against an estimate of -$0.2652.

The average analyst price target is $5.61, 434.3% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $5.61
Low
$4.04
Now
$1.05
High
$7.35

HOWL earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 31.8% on average.

  1. Q3 FY24: reported -$0.38 per share against an estimate of -$0.4204
  2. Q4 FY24: reported -$0.46 per share against an estimate of -$0.4267
  3. Q1 FY25: reported -$0.40 per share against an estimate of -$0.4019
  4. Q2 FY25: reported -$0.40 per share against an estimate of -$0.4855
  5. Q3 FY25: reported -$0.36 per share against an estimate of -$0.3978
  6. Q4 FY25: reported -$0.17 per share against an estimate of -$0.3519
  7. Q1 FY26: reported -$0.28 per share against an estimate of -$0.2907
  8. Q2 FY26: reported $0.08 per share against an estimate of -$0.2652

HOWL news

  • Press releasePRNewswire

    Are MKTX, HOWL, PSNL Obtaining Fair Deals for their Shareholders?

  • Press releasePRNewswire

    Are PSNL, MKTX, BZH, HOWL Obtaining Fair Deals for their Shareholders?

  • Press releaseBusiness Wire

    HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders

  • Press releasePRNewswire

    $HAREHOLDER ALERT: The M&A Class Action Firm Announce the Investigation of the Merger - HOWL, HZO, TYFG and FULC

  • Avi Kapoor

    Gold Moves Higher; US Composite PMI Surges In August

  • Avi Kapoor

    Dow Jumps 350 Points; BJ's Wholesale Club Posts Upbeat Earnings

  • Vandana Singh

    Werewolf Therapeutics Takes Aim At Untapped Pain Market With Ambros Deal

  • Surbhi Jain

    One of Israel Englander's Biotech Picks Just Turned Into a $500M Merger Story

Similar companies

Companies in the same industry as Werewolf Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.